Improvements in life expectancy and quality-adjusted life years as a result of chimeric antigen receptor T-cell therapy is dependent upon immediate access to treatment. READ MORE
Long-term data show that a CAR-T therapy induces significant clinical benefit without added adverse events among patients with refractory aggressive non-Hodgkin lymphoma.
CAR T-cell therapy may compliment HSCT for improving survival in ALL without increasing the risk of severe graft-versus-host disease, according to research presented at the 2018 BMT Tandem Meetings.
FDA-approved CAR T-cell therapies may be associated with high costs, but the therapies are priced in alignment with their clinical value, according to an Institute for Clinical and Economic Review evidence report.
The ICER has released a scoping document that will compare the clinical effectiveness and value of multiple CAR-T cell treatments under review by the FDA.